GLP-1 Microdosing: What the First Real-World Data Shows, and What No Trial Has Tested
Last updated: October 27, 2026 · 8 min read · By the Grey Peptides Editorial Board
- In a 2026 survey of 8,486 people using injectable GLP-1 medicines, 15% said they microdose, most often to manage side effects (41%) or cut cost (32%) 2.
- No trial of microdosing appears on PubMed, and a 2026 commentary calls high-quality evidence essentially absent 1. The trials that tested lower doses found smaller weight loss at lower doses, with gastrointestinal effects that also rose with dose 3 6.
- Splitting a weekly dose keeps the total exposure the same and narrows the swing between peak and trough; lowering the dose or stretching the interval lowers exposure.
- The labels already have a sanctioned way to take less: delay the next step, or, for tirzepatide, stay on a lower maintenance dose 9,5. Dosing accuracy is a named safety concern 1, and FDA has documented overdoses of five to 20 times the intended dose with compounded semaglutide drawn into syringes 11.
What people mean by microdosing
There is no single definition. A 2026 commentary in Expert Opinion on Pharmacotherapy says microdosing is typically defined as using 25% to 50% of the manufacturer's recommended starting dose, or extended dosing intervals, and names the techniques: "click counting" with multidose pens, or extended-interval dosing.1 The survey below used its own predefined definition, which its abstract does not print.2 People also talk about splitting a weekly dose into two injections.
These are not the same pharmacology, and the distinction matters. Splitting a dose changes the shape of the exposure but not its amount. Taking less changes the amount. Stretching the interval does both. The sections below take them in turn.
The first real-world numbers
The only sizeable data so far come from a survey presented at ISPOR 2026 in May by researchers at Evidation Health, the company that runs the online health community the respondents were drawn from.2 Of 79,602 people who answered the 51-item questionnaire, 75,886 met the analysis criteria. Among the 8,486 current users of an injectable GLP-1 medicine, 15.0% said they microdosed by the survey's definition: 9.3% currently and 5.7% in the past.
Nearly half of the current microdosers (47.6%) had started that way; the rest switched after beginning on a standard regimen. Their most common reasons were managing side effects (40.8%), reducing cost (31.9%) and supporting weight maintenance (29.6%). Current microdosers were more likely than other users to get their medicine from a source other than a healthcare provider, such as telehealth, a weight-loss clinic or a medspa. Overall satisfaction was similar between groups, but 51.0% of current microdosers expected to stop within a year. Social media was the most common source of information about microdosing across all respondents.2
It is a conference abstract, not a peer-reviewed paper, and every figure is self-reported by members of one online community. It measures how common the practice is and why people say they do it. It cannot measure whether it works.
What the trials say about lower doses
No trial of microdosing as it is practised appears on PubMed: a search on October 27, 2026 found letters, commentaries and reviews only, and the commentary calls high-quality evidence essentially absent.1 What exists are dose-ranging trials, which assigned people to fixed lower and higher doses, and they point the same way. In a 52-week phase 2 trial of daily semaglutide in 957 adults with obesity, weight fell by 6.0% on 0.05 mg a day, 8.6% on 0.1 mg, 11.6% on 0.2 mg, 11.2% on 0.3 mg and 13.8% on 0.4 mg, against 2.3% on placebo; the most common adverse events were dose-related gastrointestinal symptoms, mainly nausea.3 The lowest arm, about 0.35 mg a week in total, still did something, and did a good deal less than the higher doses.
Tirzepatide's pivotal trial tested three maintenance doses: 15.0% weight loss at 72 weeks on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo.4 The 2.5 mg starting dose was not one of the trial's maintenance doses, and Zepbound's label says it is for starting treatment and is not approved as a maintenance dose.5 In retatrutide's phase 2 trial the 1 mg arm lost 8.7% at 48 weeks against 24.2% on 12 mg, and gastrointestinal events were dose-related and partly reduced by a lower starting dose.6
So lower doses produce smaller effects, and some side effects fall with them. What no trial has tested is the specific claim behind much microdosing: that a small dose can keep off weight already lost, or produce most of the benefit with a fraction of the drug over the long term.
What splitting, cutting and stretching do to exposure
Semaglutide's half-life is about a week and tirzepatide's about five days; semaglutide peaks one to three days after an injection and tirzepatide within 8 to 72 hours.7,8 That long half-life smooths the weekly curve already. The table below uses the model behind our half-life visualizer, with the labels' half-lives and times to peak, to compare steady-state exposure under six regimens. Exposure is scaled so that the label's once-weekly dose averages 100; the amounts are relative, not milligrams.
| Drug | Regimen | Average exposure | Peak | Trough | Peak to trough |
|---|---|---|---|---|---|
| Semaglutide | The label's weekly dose | 100 | 120 | 74 | 1.61 |
| Semaglutide | Half the dose, twice a week | 100 | 106 | 90 | 1.19 |
| Semaglutide | One seventh, every day | 100 | 101 | 99 | 1.02 |
| Semaglutide | Half the dose, weekly | 50 | 60 | 37 | 1.61 |
| Semaglutide | Full dose every 10 days | 70 | 94 | 44 | 2.13 |
| Semaglutide | Full dose every 14 days | 50 | 77 | 25 | 3.12 |
| Tirzepatide | The label's weekly dose | 100 | 130 | 65 | 2.00 |
| Tirzepatide | Half the dose, twice a week | 100 | 110 | 85 | 1.29 |
| Tirzepatide | One seventh, every day | 100 | 101 | 98 | 1.03 |
| Tirzepatide | Half the dose, weekly | 50 | 65 | 32 | 2.00 |
| Tirzepatide | Full dose every 10 days | 70 | 106 | 35 | 2.98 |
| Tirzepatide | Full dose every 14 days | 50 | 91 | 18 | 5.13 |
Three things follow. Splitting the same weekly amount into two injections leaves the average exposure exactly where it was and narrows the swing between peak and trough, so whatever it does for side effects, it does not reduce how much drug the body sees. Halving the dose halves the average exposure; the swing is unchanged. Stretching the interval to 10 or 14 days lowers the average and deepens the trough before each injection. It is a model: it assumes the label's average pharmacokinetics apply to every person and every dose, which no trial has checked at doses this low.
What the labels already allow
The labels have their own answer to side effects, and it is slower, not smaller. Wegovy's says that if a patient does not tolerate a dose during escalation, the next step can be delayed by four weeks.9 Zepbound's lists three maintenance doses, 5 mg, 10 mg and 15 mg, tells prescribers to weigh response and tolerability in choosing one, and says a lower maintenance dose can be considered if a higher one is not tolerated.5 Both routes keep a person on a dose that was tested. Our titration planner lays out each label's steps.
On cost, both manufacturers sell direct to cash-paying patients at prices that depend on dose;10 the transition planner lists them with the date they were read.
Where the harm has actually been documented
The best-documented risk is not the low dose itself but measuring it. The commentary calls microdosing an off-label strategy and lists nonstandard dose measurement, dosing accuracy and compounded products among its safety concerns.1 FDA has received reports of patients giving themselves five to 20 times the intended dose of compounded semaglutide; it says unfamiliarity with drawing medicine into a syringe, together with confusion between millilitres, milligrams and "units", may have contributed.11 Our guide to insulin syringe units and the reconstitution calculator show how a unit becomes a dose.
The contents are a third. When researchers bought semaglutide from online sellers without a prescription, the vials held 29% to 39% more than their labels said, and one measured 8.95 EU/mg of bacterial endotoxin.12 A small, carefully measured dose of the wrong amount of drug is not a small dose. And the labels list their warnings, from pancreatitis and gallbladder disease to aspiration during anaesthesia, for the drug, not for particular doses.9,5
Retatrutide microdosing
Retatrutide is not approved anywhere;13 its maker reported phase 3 results in 2026 and plans to file with FDA in the first quarter of 2027.14 Any retatrutide sold for microdosing is therefore an unapproved product that no regulator has reviewed, and the lowest dose in its published phase 2 trial was the 1 mg arm described above.6 Our retatrutide hub tracks the trials and the filing timeline, and its encyclopedia entry carries the evidence.
If you are considering it
Take the question to whoever prescribes the medicine, and bring the reason. If it is side effects, ask about delaying escalation or, for tirzepatide, a lower maintenance dose, both of which the labels provide for. If it is cost, ask about the manufacturers' cash prices and whether a lower tested dose would cost less. If it is maintenance after weight loss, the honest answer is that no trial has tested a reduced dose for that purpose; the trials that stopped the drug found substantial regain within a year: two-thirds of the weight lost in the STEP 1 extension, and 14.0% of body weight regained over 52 weeks on placebo after a 20.9% loss in SURMOUNT-4.15,16 Our comparison of semaglutide and tirzepatide covers those trials, and the encyclopedia entries for semaglutide and tirzepatide carry the rest of the evidence.
Frequently asked questions
How common is GLP-1 microdosing?
In a 2026 survey of members of one online health community, 15% of 8,486 people using an injectable GLP-1 medicine said they microdosed, 9.3% currently and 5.7% in the past. It is self-reported and not yet a peer-reviewed paper.
Does microdosing a GLP-1 work?
No trial of it appears on PubMed (searched October 27, 2026). Dose-ranging trials show lower doses produce smaller weight loss: daily semaglutide at 0.05 mg lost 6.0% over a year against 13.8% at 0.4 mg.
Does splitting a weekly dose reduce side effects?
Splitting keeps the total exposure the same and narrows the peak, which may matter for some people, but we found no trial of split dosing of weekly GLP-1 medicines.
Is microdosing safer?
Some side effects fall with dose, but the labels list their serious warnings for the drug, not for particular doses, and FDA has documented overdoses of five to 20 times the intended dose when compounded semaglutide was drawn into syringes.
What can I do instead if the side effects are too much?
The labels allow a slower escalation (Wegovy: delay the next step by four weeks) and, for tirzepatide, a lower maintenance dose. Ask the prescriber.
Related on Grey Peptides
- Semaglutide vs tirzepatide
- Half-life visualizer
- GLP-1 titration planner
- Semaglutide encyclopedia entry
- Tirzepatide encyclopedia entry
- Retatrutide hub
Sources
- Beck, H. and Clements, J. N. (2026). Considerations and challenges in microdosing of GLP-1-based receptor agonists. Expert Opinion on Pharmacotherapy. Pages 1-4; PubMed date October 5, 2026. PMID: 42788826 · doi:10.1080/14656566.2026.2740393
- Ramirez, E., Lee, W.-N. and Jones, S. (2026). Emerging Patterns of GLP-1 Microdosing in a Large Real-World Population. Poster PCR123, ISPOR 2026, Philadelphia, May 2026; Value in Health, 29(S6). Abstract read on ispor.org September 30 and October 27, 2026. ISPOR
- O'Neil, P. M. et al. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet, 392(10148), 637-649. PMID: 30122305 · doi:10.1016/S0140-6736(18)31773-2
- Jastreboff, A. M. et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216. PMID: 35658024 · doi:10.1056/NEJMoa2206038
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, US prescribing information: maintenance 5 mg, 10 mg or 15 mg weekly; consider response and tolerability; 2.5 mg is for treatment initiation and not approved as a maintenance dosage; consider a lower maintenance dosage if one is not tolerated; warnings. DailyMed set 487cd7e7, version 40, effective August 28, 2026; read October 27, 2026. DailyMed
- Jastreboff, A. M. et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine, 389(6), 514-526. PMID: 37366315 · doi:10.1056/NEJMoa2301972
- Novo Nordisk. OZEMPIC (semaglutide) injection, US prescribing information, section 12.3: maximum concentration 1 to 3 days post dose; elimination half-life approximately 1 week. DailyMed set adec4fd2, version 20, effective June 1, 2026; read October 27, 2026. DailyMed
- Eli Lilly and Company. MOUNJARO (tirzepatide) injection, US prescribing information, section 12.3: time to maximum concentration 8 to 72 hours; elimination half-life approximately 5 days. DailyMed set d2d7da5d, version 40, effective August 27, 2026; read October 27, 2026. DailyMed
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets, US prescribing information: start 0.25 mg weekly, escalate every 4 weeks; usual maintenance 2.4 mg; if a dose is not tolerated during escalation, consider delaying escalation for 4 weeks; warnings. DailyMed set ee06186f, version 19, effective June 18, 2026; read October 27, 2026. DailyMed
- Eli Lilly and Company, LillyDirect Self Pay Journey Program terms for Zepbound (by dose: $299 at 2.5 mg, $399 at 5 mg, $449 at 7.5-15 mg with a 45-day refill condition), and Novo Nordisk, NovoCare Pharmacy self-pay terms for Wegovy ($349 a month for 0.25-2.4 mg pens, $399 for 7.2 mg); as published on lilly.com and novocare.com, read September 25, 2026 for our GLP-1 transition planner. Cited without a link: we name manufacturers but do not link to them.
- U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (July 26, 2024; content current as of July 26, 2024). Read October 27, 2026. FDA
- Ashraf, A. R. et al. (2024). Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of Medical Internet Research, 26, e65440. PMID: 39509151 · doi:10.2196/65440
- Eli Lilly and Company (August 12, 2026). Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market. News release (retatrutide is not approved anywhere). Cited without a link: we name manufacturers but do not link to them.
- Eli Lilly and Company (July 23, 2026). Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials. News release: Lilly plans to submit a Biologics License Application for retatrutide to FDA in Q1 2027. Cited without a link: we name manufacturers but do not link to them.
- Wilding, J. P. H. et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. PMID: 35441470 · doi:10.1111/dom.14725
- Aronne, L. J. et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38-48. PMID: 38078870 · doi:10.1001/jama.2023.24945
This article describes survey data, trials and labels. It is not medical advice, and nothing here recommends any dose. Changing a dose of a prescription medicine is a decision to make with the prescriber.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead